EGFR and colorectal carcinoma: RAS mutations cause oncogenic activation independent of epidermal growth factor–epidermal growth factor receptor signal transmission, resulting in a lack of response to anti-epidermal growth factor receptor antibodies.9 To overcome this resistance mechanism, the identification of downstream molecules that show potential as new therapeutic targets for RAS-mutated CRC has become an important focus.